MaxCyte, Inc. provided revenue guidance for the full year 2022. For the period, the company expected core business revenue (instruments and disposables to cell therapy and drug discovery customers and excluding program-related revenue) to grow at least 25% compared to 2021 core business revenue. The company also continue to expect SPL Program-related revenue to be approximately $4 million in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
322 GBX | 0.00% |
|
-2.42% | -8.65% |
11/06 | MaxCyte CEO Maher Masoud buys 100,000 shares | AN |
11/06 | Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.65% | 43Cr | |
+8.00% | 19TCr | |
+31.86% | 16TCr | |
+33.21% | 11TCr | |
+2.28% | 6.43TCr | |
+21.14% | 5.57TCr | |
+0.11% | 4.84TCr | |
-6.76% | 3.78TCr | |
+0.78% | 3.56TCr | |
+11.28% | 2.81TCr |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Provides Revenue Guidance for the Full Year 2022